Plasma gelsolin as a biomarker of inflammation

por DiNubile, Mark J
Publicado em 2008

Noninferior Antibiotics: When Is “Not Bad” “Good Enough”?

por DiNubile, Mark J.
Publicado no Open Forum Infect Dis (2016)

Unexpectedly high burden of rotavirus gastroenteritis in very young infants

por Clark, H Fred, Marcello, Amy E, Lawley, Diane, Reilly, Megan, DiNubile, Mark J
Publicado em 2010

Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Nonsevere Community-Acquired Pneumonia

por Tannous, Abla, Levinson, Susan L., Bolognese, James, Opal, Steven M., DiNubile, Mark J.
Publicado no Antimicrob Agents Chemother (2020)

Decline in Cases of Rotavirus Gastroenteritis Presenting to The Children's Hospital of Philadelphia after Introduction of a Pentavalent Rotavirus Vaccine

por Clark, H Fred, Lawley, Diane, Mallette, Laura A., DiNubile, Mark J., Hodinka, Richard L.
Publicado em 2009

Recombinant Human Plasma Gelsolin Improves Survival and Attenuates Lung Injury in a Murine Model of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia

por DiNubile, Mark J, Levinson, Susan L, Stossel, Thomas P, Lawrenz, Matthew B, Warawa, Jonathan M
Publicado no Open Forum Infect Dis (2020)

Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases

por Arathoon, Eduardo G., Gotuzzo, Eduardo, Noriega, L. Miguel, Berman, Rayanne S., DiNubile, Mark J., Sable, Carole A.
Publicado em 2002

Acquisition of Resistant Bowel Flora during a Double-Blind Randomized Clinical Trial of Ertapenem versus Piperacillin-Tazobactam Therapy for Intraabdominal Infections

por DiNubile, Mark J., Chow, Joseph W., Satishchandran, Vilas, Polis, Adam, Motyl, Mary R., Abramson, Murray A., Teppler, Hedy
Publicado em 2005

Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV...

por Itzler, Robbin, Koch, Gary, Matson, David O, Gothefors, Leif, Van Damme, Pierre, DiNubile, Mark J, Heaton, Penny M
Publicado em 2010

Staphylococcus aureus Infections After Elective Cardiothoracic Surgery: Observations From an International Randomized Placebo-Controlled Trial of an Investigational S aureus Vaccin...

por Allen, Keith B., Fowler, Vance G., Gammie, James S., Hartzel, Jonathan S., Onorato, Matthew T., DiNubile, Mark J., Sobanjo-ter Meulen, Ajoke
Publicado no Open Forum Infect Dis (2014)

Therapeutic potential of plasma gelsolin administration in a rat model of sepsis

por Cohen, Taylor S., Bucki, Robert, Byfield, Fitzroy J., Ciccarelli, Nicholas J., Rosenberg, Brenna, DiNubile, Mark J., Janmey, Paul A., Margulies, Susan S.
Publicado em 2011

Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: An analysis of possible contributing host factors

por McNeely, Tessie B, Shah, Najaf A, Fridman, Arthur, Joshi, Amita, Hartzel, Jonathan S, Keshari, Ravi S, Lupu, Florea, DiNubile, Mark J
Publicado no Hum Vaccin Immunother (2014)

Safety and Immunogenicity of a Novel Staphylococcus aureus Vaccine: Results from the First Study of the Vaccine Dose Range in Humans

por Harro, Clayton, Betts, Robert, Orenstein, Walter, Kwak, Eun-Jeong, Greenberg, Howard E., Onorato, Matthew T., Hartzel, Jon, Lipka, Joy, DiNubile, Mark J., Kartsonis, Nicholas
Publicado em 2010

Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin

por Howe, John A., Long, Jianmin, Black, Stuart, Chase, Robert, McMonagle, Patricia, Curry, Stephanie, Thompson, Seth, DiNubile, Mark J., Howe, Anita Y. M.
Publicado no Open Forum Infect Dis (2014)

Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without Adjuvants

por Quirk, Erin K., Brown, Elizabeth L., Leavitt, Randi Y., Mogg, Robin, Mehrotra, Devan V., Evans, Robert K., DiNubile, Mark J., Robertson, Michael N.
Publicado no Open Forum Infect Dis (2014)

Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analy...

por Squires, Kathleen, Bekker, Linda-Gail, Katlama, Christine, Yazdanpanah, Yazdan, Zhou, Yan, Rodgers, Anthony J., DiNubile, Mark J., Sklar, Peter A., Leavitt, Randi Y., Teppler, Hedy
Publicado no Open Forum Infect Dis (2017)

Phase IIa Study of the Immunogenicity and Safety of the Novel Staphylococcus aureus Vaccine V710 in Adults with End-Stage Renal Disease Receiving Hemodialysis

por Moustafa, Moustafa, Aronoff, George R., Chandran, Chandra, Hartzel, Jonathan S., Smugar, Steven S., Galphin, Claude M., Mailloux, Lionel U., Brown, Elizabeth, DiNubile, Mark J., Kartsonis, Nicholas A., Guris, Dalya
Publicado em 2012

Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults

por Harro, Clayton, Sun, Xiao, Stek, Jon E., Leavitt, Randi Y., Mehrotra, Devan V., Wang, Fubao, Bett, Andrew J., Casimiro, Danilo R., Shiver, John W., DiNubile, Mark J., Quirk, Erin
Publicado em 2009

Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients

por Papasavvas, Emmanouil, Pistilli, Maxwell, Reynolds, Griffin, Bucki, Robert, Azzoni, Livio, Chehimi, Jihed, Janmey, Paul A., DiNubile, Mark J., Ondercin, Joe, Kostman, Jay R., Mounzer, Karam C., Montaner, Luis J.
Publicado em 2009

Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults

por Harro, Clayton, Sun, Xiao, Stek, Jon E., Leavitt, Randi Y., Mehrotra, Devan V., Wang, Fubao, Bett, Andrew J., Casimiro, Danilo R., Shiver, John W., DiNubile, Mark J., Quirk, Erin
Publicado em 2010